Asterias Biotherapeutics Inc Class A
(NYSE Amex Equities : AST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.55%89.141.3%$797.85m
AMGNAmgen Inc.
1.08%187.501.2%$644.97m
GILDGilead Sciences, Inc.
0.29%65.740.9%$476.37m
BIIBBiogen Inc.
1.30%325.331.3%$432.61m
ILMNIllumina, Inc.
1.41%301.063.5%$311.78m
REGNRegeneron Pharmaceuticals, Inc.
0.93%422.522.6%$280.54m
VRTXVertex Pharmaceuticals Incorporated
1.48%185.761.9%$246.69m
ALXNAlexion Pharmaceuticals, Inc.
1.71%129.732.0%$214.36m
SRPTSarepta Therapeutics, Inc.
2.52%139.9815.4%$157.00m
AAgilent Technologies, Inc.
0.67%78.411.6%$155.05m
EXASExact Sciences Corporation
10.52%92.0425.3%$150.72m
INCYIncyte Corporation
1.82%84.852.5%$112.02m
ARRYArray BioPharma Inc.
2.33%23.248.2%$111.41m
NBIXNeurocrine Biosciences, Inc.
2.07%78.915.1%$80.47m
EXELExelixis, Inc.
1.41%21.526.4%$79.74m

Company Profile

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.